

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT PROPOSED APPOINTMENT OF AUDITORS

This announcement is made by Sinopharm Group Co. Ltd. (the “**Company**”) pursuant to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the announcement of the Company dated 7 June 2024, in relation to withdrawal of a resolution regarding the appointment of PricewaterhouseCoopers and PricewaterhouseCoopers Zhong Tian LLP (collectively, “**PwC**”) as the international auditor and the domestic auditor of the Company for the year (the “**Auditors for the Year**”) at the annual general meeting held on 13 June 2024, and the announcement of the Company dated 13 June 2024, in relation to poll results of the annual general meeting. The term of service of PwC has expired and PwC retired from the Auditors for the Year. The board of directors of the Company (the “**Board**”) would like to take this opportunity to express its sincere gratitude to PwC for its professional services provided to the Company for the past years.

In view of market information, based on the principle of prudence, and taking into account of the current business situations, development needs and overall audit needs of the Company, the Company conducted a tendering process for the selection of Auditors for the Year 2024 in order to ensure the smooth progress of the audit work on the Company's financial statements after PwC retired from the Auditors for the Year. Based on the result of the tender and the recommendation of the audit committee (the “**Audit Committee**”) of the Board, the Board proposed to appoint Confucius International CPA Limited and Pan-China Certified Public Accountants LLP (collectively, “**Pan-China**”) as the international auditor and the domestic auditor of the Company for the year of 2024 (the “**Proposed Appointment of the Auditors for the Year 2024**”), respectively. When recommending the appointment of Pan-China as the Auditors for the Year 2024, the Audit Committee and the Board considered the background, scale, qualifications, competence, experience, resource allocation, diversified service capabilities and other aspects of Pan-China, and were of view that Pan-China was qualified and suitable to serve as the Auditors for the Year 2024. The term of service of Pan-China will commence from the date on which the relevant resolution is approved by the shareholders at the extraordinary general meeting up to the date of the next annual general meeting of the Company to be held in 2025. The Proposed Appointment of the Auditors for the Year 2024 is subject to the approval of the shareholders at the extraordinary general meeting.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

A circular containing, among other things, further details of the Proposed Appointment of the Auditors for 2024, together with a notice of the extraordinary general meeting of the Company, will be dispatched to the shareholders according to the manner in which the shareholders of the Company have elected to receive corporate communications in due course.

By order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC
23 August 2024

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.